Artwork

Content provided by McGuireWoods Consulting. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McGuireWoods Consulting or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

New CMS Guidelines for Drug Price Negotiation

9:04
 
Distribuie
 

Manage episode 418533912 series 3474130
Content provided by McGuireWoods Consulting. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McGuireWoods Consulting or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

The Center for Medicaid & Medicare Services (CMS) recently released new guidelines that will affect the Medicare drug price negotiation process beginning in 2026.

In this episode of Complications: Health Policy Unraveled, host Stephanie Kennan provides a summary of the new CMS guidelines, including the new requirements for drug manufacturers and Part D dispensing entities, the timeline for negotiating new drug prices, and some of the challenges in navigating these new guidelines. Tune in to learn more about these new CMS guidelines.

Meet Your Host

Name: Stephanie Kennan

Title: Senior Vice President, Federal Public Affairs at McGuireWoods Consulting

Specialty: Stephanie Kennan helps clients navigate the legislative and executive branches of the federal government to solve problems involving a variety of healthcare policy issues. Her work focuses on providers, medical device manufacturers, drug manufacturers and associations concerned about Medicare and Medicaid reimbursement.

Connect: LinkedIn

Episode Highlights

[0:30] An overview of the new CMS drug price negotiation guidelines

[1:21] The limited effect of the Inflation Reduction Act on Medicare drug price negotiations

[1:39] The process of negotiating new maximum fair prices for drugs between Medicare and drug manufacturers.

[3:18] How the new guidelines mandate patient access to drugs

[5:28] Using a Medicare Transaction Facilitator to ensure the guidelines are followed by engaging in an exchange of information between drug manufacturers and CMS

[7:02] CMS’s procedures for receiving feedback on certain features of the new guidelines

Contact

Connect with us on Facebook, Twitter, LinkedIn, YouTube.

Subscribe to Complications: Health Policy Unraveled in your preferred podcast app and never miss a healthcare update by subscribing to host and JD Supra’s #1 healthcare author Stephanie Kennan’s Washington Healthcare Update at www.mwcllc.com

  continue reading

36 episoade

Artwork
iconDistribuie
 
Manage episode 418533912 series 3474130
Content provided by McGuireWoods Consulting. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by McGuireWoods Consulting or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

The Center for Medicaid & Medicare Services (CMS) recently released new guidelines that will affect the Medicare drug price negotiation process beginning in 2026.

In this episode of Complications: Health Policy Unraveled, host Stephanie Kennan provides a summary of the new CMS guidelines, including the new requirements for drug manufacturers and Part D dispensing entities, the timeline for negotiating new drug prices, and some of the challenges in navigating these new guidelines. Tune in to learn more about these new CMS guidelines.

Meet Your Host

Name: Stephanie Kennan

Title: Senior Vice President, Federal Public Affairs at McGuireWoods Consulting

Specialty: Stephanie Kennan helps clients navigate the legislative and executive branches of the federal government to solve problems involving a variety of healthcare policy issues. Her work focuses on providers, medical device manufacturers, drug manufacturers and associations concerned about Medicare and Medicaid reimbursement.

Connect: LinkedIn

Episode Highlights

[0:30] An overview of the new CMS drug price negotiation guidelines

[1:21] The limited effect of the Inflation Reduction Act on Medicare drug price negotiations

[1:39] The process of negotiating new maximum fair prices for drugs between Medicare and drug manufacturers.

[3:18] How the new guidelines mandate patient access to drugs

[5:28] Using a Medicare Transaction Facilitator to ensure the guidelines are followed by engaging in an exchange of information between drug manufacturers and CMS

[7:02] CMS’s procedures for receiving feedback on certain features of the new guidelines

Contact

Connect with us on Facebook, Twitter, LinkedIn, YouTube.

Subscribe to Complications: Health Policy Unraveled in your preferred podcast app and never miss a healthcare update by subscribing to host and JD Supra’s #1 healthcare author Stephanie Kennan’s Washington Healthcare Update at www.mwcllc.com

  continue reading

36 episoade

Все серии

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință

Listen to this show while you explore
Play